Clinical Trial Update: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 randomized trial of palbociclib for metastatic breast cancer has results posted and the study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Alliance Foundation Trials, LLC. | Conditions: HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-12